By Iain Gilbert
Date: Wednesday 10 Mar 2021
LONDON (ShareCast) - (Sharecast News) - Rapid tests developer Abingdon Health has signed a non-exclusive sales and distribution agreement in the UK and Europe for its AbC-19 rapid neutralising antibody test with BioSure UK.
Abingdon said on Wednesday that it will establish a strategic distribution relationship with BioSure to enable both firms to identify and maximise opportunities for the sale of the AbC-19 rapid neutralising antibody test in the UK and European territories.
The AIM-listed group stated healthcare, workplace and pharmacy settings will be prioritised, with antibody testing becoming "even more relevant" as vaccination programmes scale.
Chief executive Chris Yates said: "The nature of SARS-CoV-2 testing is changing. Where antibody tests were once predominantly used for charting the spread of infection within communities, today they emerging as a key pillar of large-scale immunisation campaigns.
"Rapid Antibody tests such as AbC-19 that target the full trimeric spike can help policymakers and healthcare networks further understand immunity to Covid-19 and the effectiveness of vaccine programmes."
As of 1050 GMT, Abingdon shares had shot up 7.40% to 103.64p.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 9.25p |
Change Today | -0.50p |
% Change | -5.13 % |
52 Week High | 15.00 |
52 Week Low | 5.00 |
Volume | 125,825 |
Shares Issued | 121.72m |
Market Cap | £11.26m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:19 | 1,000 @ 9.50p |
16:01 | 13 @ 9.50p |
15:58 | 4,742 @ 9.18p |
15:40 | 200 @ 9.50p |
15:40 | 20 @ 9.00p |
You are here: research